Humacyte, Inc. filings document a commercial-stage biotechnology issuer built around acellular tissue engineered vessels and related bioengineered human tissue programs. Its reports and 8-K filings cover operating results, product commercialization, clinical and regulatory disclosures, material agreements for Symvess distribution rights, and collaboration or licensing arrangements.
The company’s SEC record also includes capital-structure disclosures for common stock and redeemable warrants, equity offering arrangements, secured debt financing, and Nasdaq listing-rule notices. Proxy materials describe board matters, executive compensation, equity awards, shareholder voting items and other governance disclosures for HUMA.
Humacyte reported early commercial activity for Symvess and maintained meaningful liquidity while continuing R&D spending. Cash and cash equivalents were $38.0 million with restricted cash of $50.2 million, totaling $88.4 million of cash and restricted cash. Total assets were $138.8 million and stockholders' equity was $4.1 million. The company recognized product and contract revenue of $0.3 million in Q2 2025 and $0.8 million for the six months ended June 30, 2025, and capitalized $11.1 million of inventory related to Symvess.
Operating expenses remained high: R&D was $37.4 million for six months and the operating loss was $52.9 million for the same period. Net results for the six months show a $1.5 million net income driven largely by a $44.3 million favorable change in the fair value of a contingent earnout liability, while the three‑month period posted a $37.7 million net loss. Financing activity included a $46.7 million public offering (net) and ATM proceeds of $3.6 million in the first half of 2025. The company implemented workforce reductions and expects existing cash plus available equity commitments to fund operations for at least twelve months from these interim statements.
Humacyte, Inc. furnished a press release reporting its financial results for the fiscal second quarter ended June 30, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference into this Current Report, but the body of the Form 8-K does not include the underlying financial figures or tables.
The filing explicitly states that the information, including the exhibit, "shall not be deemed filed" for purposes of Section 18 of the Exchange Act and will not be incorporated by reference in other filings except by specific reference. The report also identifies the company as an emerging growth company and lists its securities as Common Stock (HUMA) and Redeemable Warrants (HUMAW) on Nasdaq. The filing includes Exhibit 99.1 and the Cover Page Interactive Data File (Exhibit 104).